Charles River Laboratories International, Inc. CRL
We take great care to ensure that the data presented and summarized in this overview for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRL
View all-
Vanguard Group Inc Valley Forge, PA5.81MShares$888 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.09MShares$777 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA3.77MShares$576 Million0.11% of portfolio
-
Allspring Global Investments Holdings, LLC2.29MShares$350 Million0.63% of portfolio
-
State Street Corp Boston, MA1.86MShares$284 Million0.01% of portfolio
-
Nomura Holdings Inc Tokyo, M01.57MShares$240 Million0.52% of portfolio
-
Ariel Investments, LLC Chicago, IL1.42MShares$216 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA1.24MShares$189 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA1.23MShares$188 Million0.01% of portfolio
-
Harris Associates L P Chicago, IL1.16MShares$178 Million0.3% of portfolio
Latest Institutional Activity in CRL
Top Purchases
Top Sells
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Transactions at CRL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 18
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Open market or private sale
|
Direct |
800
-3.21%
|
$125,600
$157.6 P/Share
|
Aug 07
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Open market or private sale
|
Direct |
400
-1.58%
|
$60,000
$150.04 P/Share
|
Jun 05
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Bona fide gift
|
Direct |
385
-1.5%
|
-
|
Jun 02
2025
|
Abraham Ceesay Director |
BUY
Grant, award, or other acquisition
|
Direct |
946
+50.0%
|
$127,710
$135.04 P/Share
|
Jun 02
2025
|
Paul W Graves Director |
BUY
Grant, award, or other acquisition
|
Direct |
946
+50.0%
|
$127,710
$135.04 P/Share
|
Jun 02
2025
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
946
+50.0%
|
$127,710
$135.04 P/Share
|
Jun 02
2025
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,427
+44.93%
|
$192,645
$135.04 P/Share
|
Jun 01
2025
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-2.09%
|
$30,375
$135.63 P/Share
|
May 31
2025
|
Flavia Pease Corporate Executive VP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
185
-1.06%
|
$24,975
$135.63 P/Share
|
May 31
2025
|
Shannon M Parisotto CEVP, Disc & Safety Assessment |
SELL
Payment of exercise price or tax liability
|
Direct |
105
-0.8%
|
$14,175
$135.63 P/Share
|
May 31
2025
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-0.44%
|
$6,480
$135.63 P/Share
|
May 31
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Payment of exercise price or tax liability
|
Direct |
155
-0.6%
|
$20,925
$135.63 P/Share
|
May 31
2025
|
Birgit Girshick Corporate Executive VP & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
283
-0.43%
|
$38,205
$135.63 P/Share
|
May 31
2025
|
Victoria L Creamer EVP & Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-0.53%
|
$16,200
$135.63 P/Share
|
May 30
2025
|
Flavia Pease Corporate Executive VP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,152
+29.03%
|
$965,520
$135.63 P/Share
|
May 30
2025
|
Shannon M Parisotto CEVP, Disc & Safety Assessment |
BUY
Grant, award, or other acquisition
|
Direct |
5,603
+29.95%
|
$756,405
$135.63 P/Share
|
May 30
2025
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,064
+16.04%
|
$278,640
$135.63 P/Share
|
May 30
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
BUY
Grant, award, or other acquisition
|
Direct |
6,709
+20.6%
|
$905,715
$135.63 P/Share
|
May 30
2025
|
Birgit Girshick Corporate Executive VP & COO |
BUY
Grant, award, or other acquisition
|
Direct |
12,239
+15.6%
|
$1,652,265
$135.63 P/Share
|
May 30
2025
|
James C Foster Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,253
+7.57%
|
$2,329,155
$135.63 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 103K shares |
---|---|
Open market or private purchase | 7.59K shares |
Payment of exercise price or tax liability | 15.1K shares |
---|---|
Bona fide gift | 10.3K shares |
Open market or private sale | 14K shares |